Education
About Us
Working with TipRanks
Follow Us
Valneva (VALN)
NASDAQ:VALN
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.27Last Year’s EPS
-0.38Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: -3.24%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive financial performance with significant revenue growth and improved gross margins, alongside challenges related to safety concerns for IXCHIQ and an operating loss. The overall sentiment is balanced, reflecting both substantial achievements and notable challenges.Company Guidance
During the first quarter of fiscal year 2025, Valneva reported a strong financial performance with total revenues reaching nearly €50 million, a 51.2% increase in product sales compared to the same period last year. Key achievements include a cash position exceeding €150 million, boosted by a €14.2 million ATM transaction in April, and significant progress in regulatory approvals for IXCHIQ, notably in the UK, Europe, and Brazil. The company highlighted the continuation of its Phase 3 Lyme disease study, VALOR, which involves over 9,000 participants and is expected to yield data by year-end, with potential regulatory filings anticipated next year. Valneva maintained its full-year guidance, projecting product sales between €170 million and €180 million, and total revenues of €180 million to €190 million. The company also reported an operating loss of €6 million for the quarter, compared to a profit of €68.2 million the previous year, largely due to a non-recurring revenue from a Priority Review Voucher sale in 2024. Looking forward, Valneva expects sustained profitability from 2027, contingent on Lyme disease vaccine approval and commercialization.Strong Revenue Growth
Total revenues for Q1 2025 reached €49.2 million, a significant increase from €32.8 million in Q1 2024. Product sales rose by 51.2% year-over-year.
IXIARO Sales Increase
IXIARO sales reached €27.5 million, a 65.5% increase from the previous year, driven by strong sales to the US military and travel channels.
Improved Gross Margins
Gross margin on commercial products excluding IXCHIQ improved to 62.7% from 43.9% in Q1 2024, due to better manufacturing performance and fewer batch failures.
Regulatory Achievements
Valneva received marketing authorization for IXCHIQ in the UK, Europe, and Brazil, and submitted a label extension application for adolescents.
Lyme Disease Vaccine Progress
Progress in the Phase 3 study for the Lyme disease vaccine, VALOR, with expected data by the end of the year.
VALN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VALN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $6.48 | $6.59 | +1.70% |
Mar 20, 2025 | $6.73 | $7.25 | +7.73% |
Nov 07, 2024 | $5.59 | $5.48 | -1.97% |
Aug 13, 2024 | $6.94 | $7.45 | +7.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Valneva (VALN) report earnings?
Valneva (VALN) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Valneva (VALN) earnings time?
Valneva (VALN) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VALN EPS forecast?
VALN EPS forecast for the fiscal quarter 2025 (Q2) is -0.27.